[ Tips ] 一分鐘使用導覽
商品編號： UV6874 出版日期： 2014/10/22 作者姓名： Eades, Kenneth;Matos, Pedro;Aleyev, Dmitriy;Xu, Chong 商品類別： Finance 商品規格： 24p 再版日期： 2018/06/21 地域： 產業： Biotechnology;Pharmaceuticals 個案年度： -
商品敘述：
This case is designed to be part of an MBA corporate finance class. In October 2010, Henri Termeer, the chairman and CEO of Genzyme (a top-five biotechnology company), received a letter from the CEO of Sanofi-Aventis (a large French pharmaceutical company) announcing its intention to commence a tender offer for Genzyme. Termeer thought the offer undervalued Genzyme given the number of promising new drugs in the company''s pipeline and the success of its current drug portfolio. To estimate Genzyme''s fundamental value, Termeer and his finance team would need to conduct a discounted cash flow (DCF) and other valuation analyses. Termeer needed to be well prepared for the board meeting during which the response to the offer would be formulated.
涵蓋領域：
Cash flow statements;Mergers & acquisitions
相關資料：
Case Teaching Note, (UV6875), 14p, by Kenneth Eades;Spreadsheet Supplement, (UV6876), 22p, by Kenneth Eades, Dmitriy Aleyev, Chong Xu;Spreadsheet Supplement, (UV6877), 20p, by Kenneth Eades, Dmitriy Aleyev, Chong Xu
哪些人也有訂購？